|
1
|
Yang JC, Sherry RM, Steinberg SM, et al:
Randomized study of high-dose and low-dose interleukin-2 in
patients with metastatic renal cancer. J Clin Oncol. 21:3127–3132.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fyfe G, Fisher RI, Rosenberg SA, et al:
Results of treatment of 255 patients with metastatic renal cell
carcinoma who received high-dose recombinant interleukin-2 therapy.
J Clin Oncol. 13:688–696. 1995.
|
|
3
|
Dangaj D, Lanitis E, Zhao A, et al: Novel
recombinant human b7-h4 antibodies overcome tumoral immune escape
to potentiate T cell antitumor responses. Cancer Res. 73:4820–4829.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tringler B, Zhuo S, Pilkington G, et al:
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin
Cancer Res. 11:1842–1848. 2005. View Article : Google Scholar
|
|
5
|
Kryczek I, Zou L, Rodriguez P, et al:
B7-H4 expression identifies a novel suppressive macrophage
population in human ovarian carcinoma. J Exp Med. 203:871–881.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choi IH, Zhu G, Sica GL, et al: Genomic
organization and expression analysis of B7-H4, an immune inhibitory
molecule of the B7 family. J Immunol. 171:4650–4654. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun Y, Wang Y, Zhao J, et al: B7-H3 and
B7-H4 expression in non-small-cell lung cancer. Lung cancer.
53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Quandt D, Fiedler E, Boettcher D, et al:
B7-h4 expression in human melanoma: its association with patients’
survival and antitumor immune response. Clin Cancer Res.
17:3100–3111. 2011.PubMed/NCBI
|
|
9
|
Krambeck AE, Thompson RH, Dong H, et al:
B7-H4 expression in renal cell carcinoma and tumor vasculature:
associations with cancer progression and survival. Proc Natl Acad
Sci USA. 103:10391–10396. 2006. View Article : Google Scholar
|
|
10
|
Bromwich EJ, McArdle PA, Canna K, et al:
The relationship between T-lymphocyte infiltration, stage, tumour
grade and survival in patients undergoing curative surgery for
renal cell cancer. Br J Cancer. 89:1906–1908. 2003. View Article : Google Scholar
|
|
11
|
Nakano O, Sato M, Naito Y, et al:
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a
prognostic factor in human renal cell carcinoma: clinicopathologic
demonstration of antitumor immunity. Cancer Res. 61:5132–5136.
2001.
|
|
12
|
Couillard DR and DeVere-White RW: Surgery
of renal cell carcinoma. Urol Clin North Am. 20:263–275. 1993.
|
|
13
|
Zang X, Loke P, Kim J, et al: B7x: a
widely expressed B7 family member that inhibits T cell activation.
Proc Natl Acad Sci USA. 100:10388–10392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prasad DV, Richards S, Mai XM and Dong C:
B7S1, a novel B7 family member that negatively regulates T cell
activation. Immunity. 18:863–873. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sica GL, Choi IH, Zhu G, et al: B7-H4, a
molecule of the B7 family member, negatively regulates T cell
immunity. Immunity. 18:849–861. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kryczek I, Wei S, Zhu G, et al:
Relationship between B7-H4, regulatory T cells, and patient outcome
in human ovarian carcinoma. Cancer Res. 67:8900–8905. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brahmer JR, Tykodi SS, Chow LQ, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Topalian SL, Hodi FS, Brahmer JR, et al:
Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ribas A: Tumor immunotherapy directed at
PD-1. N Eng J Med. 366:2517–2519. 2012. View Article : Google Scholar : PubMed/NCBI
|
